The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

被引：0
|
作者：
Kazuomi Kario
机构：
[1] Jichi Medical University School of Medicine (JMU),Division of Cardiovascular Medicine, Department of Medicine
[2] JMU Center of Excellence,undefined
[3] Community Medicine Cardiovascular Research and Development (JCARD),undefined
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Sacubitril/valsartan; Angiotensin receptor neprilysin inhibitor (ARNI); Resistant hypertension; Cardiovascular continuum; Nocturnal hypertension; Systolic hypertension; Central blood pressure; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
    Kario, Kazuomi
    Tamaki, Yuko
    Okino, Naoko
    Gotou, Hiromi
    Zhu, Min
    Zhang, Jack
    JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (04): : 308 - 314
  • [22] Angiotensin receptor-neprilysin inhibiton (ARNI) - A novel therapeutic concept for management of hypertension and heart failure
    Kjeldsen, Sverre E.
    Hedner, Thomas
    Narkiewicz, Krzysztof
    Oparil, Suzanne
    BLOOD PRESSURE, 2012, 21 (06) : 329 - 330
  • [23] Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM
    Lillyblad, Matthew P.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (11) : 1237 - 1251
  • [24] Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
    Xinyue Dong
    Xiaoning He
    Jing Wu
    PharmacoEconomics, 2022, 40 : 1187 - 1205
  • [25] Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs
    Gori, Mauro
    Volterrani, Maurizio
    Piepoli, Massimo
    Senni, Michele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 226 : 136 - 140
  • [26] Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
    Singh, Jagdeep S. S.
    Lang, Chim C.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 283 - 295
  • [27] Angiotensin Neprilysin Inhibition for Patients With Heart Failure What If Sacubitril/Valsartan Were a Treatment for Cancer?
    Packer, Milton
    JAMA CARDIOLOGY, 2016, 1 (09) : 971 - 972
  • [28] Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
    Ito, Sadayoshi
    Satoh, Minoru
    Tamaki, Yuko
    Gotou, Hiromi
    Charney, Alan
    Okino, Naoko
    Akahori, Mizuki
    Zhang, Jack
    HYPERTENSION RESEARCH, 2015, 38 (04) : 269 - 275
  • [29] Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction
    Sadayoshi Ito
    Minoru Satoh
    Yuko Tamaki
    Hiromi Gotou
    Alan Charney
    Naoko Okino
    Mizuki Akahori
    Jack Zhang
    Hypertension Research, 2015, 38 : 269 - 275
  • [30] ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS (ARNI) POTENTIALS IN PATIENT WITH HEART FAILURE: A SYSTEMATIC REVIEW
    Puratmaja, Nalagafiar
    Sjarfi, Cheras Yezia Kharismia
    JOURNAL OF HYPERTENSION, 2020, 38 : E7 - E7
12345